Alimera Sciences, Inc.

NasdaqGM:ALIM Stok Raporu

Piyasa değeri: US$301.3m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Alimera Sciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Alimera Sciences şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.03%

Geri Alım Getirisi

Toplam Hissedar Getirisi-0.03%
Gelecekteki Temettü Verimin/a
Temettü Büyümesin/a
Bir sonraki temettü ödeme tarihin/a
Eski temettü tarihin/a
Hisse başına temettün/a
Ödeme oranın/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Seeking Alpha • Sep 11

Alimera Sciences: Deal Closing After All, CVR Still Attractive

Summary Alimera Sciences, Inc. is being acquired by ANI Pharmaceuticals for $5.50 per share, with a contingent value right, or CVR, potentially adding up to $0.50 per share. Despite initial delays and Alimera suing ANI to close the deal, ANI remains committed, expecting to resolve closing conditions promptly. The deal is highly synergistic, adding durable assets to ANI's portfolio, with significant revenue growth and accretion expected by 2025. At $5.54 per share, Alimera Sciences stock is attractive, offering potential CVR payouts based on achievable sales targets, making it a compelling investment. Read the full article on Seeking Alpha
Seeking Alpha • Jul 16

Alimera Sciences: Cheap CVR Optionality

Summary Alimera Sciences is being acquired by a larger peer at $5.5/share + CVR of up to 50 cents. In this article, I will focus on a CVR play with only a 10-cent outlay and a potential payout of up to 50 cents. The merger-related risks are minimal, and there are arguments that suggest the CVR milestones could be met. Read the full article on Seeking Alpha
Analiz Makalesi • Jun 18

Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)

You may think that with a price-to-sales (or "P/S") ratio of 1.9x Alimera Sciences, Inc. ( NASDAQ:ALIM ) is a stock...
Analiz Makalesi • Feb 15

Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Alimera Sciences, Inc.'s ( NASDAQ:ALIM ) price-to-sales (or "P/S") ratio of 2.6x might make it look like a buy right...
Analiz Makalesi • Dec 30

Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analiz Makalesi • Oct 13

Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)

There wouldn't be many who think Alimera Sciences, Inc.'s ( NASDAQ:ALIM ) price-to-sales (or "P/S") ratio of 2.5x is...
Analiz Makalesi • Sep 13

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Oct 06

Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data

Alimera Sciences (NASDAQ:ALIM) said on Thursday a post-hoc analyses from a Phase 4 study showed that median treatment frequency in diabetic macular edema patients treated with its therapy Iluvien 0.19 mg was lower than from patients on other regimens. Iluvien provides diabetic macular edema patients with continuous therapy for up to 36 months. The treatment significantly reduced the number of eyes requiring anti-VEGF, corticosteroid, and laser therapy and reduced the total number of therapies administered by 46%. Iluvien is a intravitreal implant in the United States for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
Seeking Alpha • Sep 20

Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland

Alimera Sciences (NASDAQ:ALIM) on Tuesday said it had been granted reimbursement for its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in Ireland. ALIM said the reimbursement was granted to the its Ireland-based European unit by the Health Service Executive Corporate Pharmaceutical Unit and National Centre for Pharmacoeconomics in Ireland. The reimbursement decision by Ireland adds to a string of such grants earlier this year by Portugal, France and Italy. "We continue to expand the availability of our non-infectious uveitis indication in our International Segment with it now accessible to patients in all of our direct markets in addition to our key distributor markets," ALIM CEO Rick Eiswirth said in a statement. ALIM stock closed -3.6% at $5.38 on Monday.
Seeking Alpha • Aug 09

Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection

Alimera Sciences (NASDAQ:ALIM) on Tuesday said it had been granted reimbursement for its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in Portugal. ALIM said the reimbursement was granted by Portugal's National Authority of Medicines and Health Products with no change to the current label. The reimbursement decision by Portugal follows similar approvals for Iluvien in France and Italy in July. “This summer has been a productive one for expanding availability of our non-infectious uveitis indication in our International Segment with it soon to be accessible to patients in all of our direct markets in addition to our key distributor markets,” ALIM CEO Rick Eiswirth said in a statement. ALIM said it is planning to launch Iluvien in Portugal and France in Q3. Alimera (ALIM) stock closed +2.6% at $7.18 on Monday.
Seeking Alpha • Jul 22

Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection

Alimera Sciences (NASDAQ:ALIM) on Friday said it would launch its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in France through its distribution partner Horus Pharma. ALIM said Horus had been granted pricing and reimbursement approval for Iluvien for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye from the Economics Committee for Health Products. Alimera (ALIM) did not disclose the pricing determination for Iluvien. Earlier in July, ALIM got Italian regulatory approval and was granted pricing and reimbursement for Iluvien for the same indication. ALIM stock closed +0.8% at $5.33 on Thursday.
Seeking Alpha • Jul 08

Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation

Alimera Sciences (NASDAQ:ALIM) has got Italian regulatory approval for its Iluvien injection for the treatment of uveitis, a form of eye inflammation. ALIM's Ireland-based European unit, Alimera Sciences Europe, got an approval and was granted pricing and reimbursement for Iluvien by the Italian Medicines Agency (AIFA), Alimera said in a statement on Friday. The indication was for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. ALIM said it would launch Iluvien through its Italian distribution partner, ophthalmic company SIFI. It did not disclose the pricing determination for Iluvien. ALIM stock closed marginally higher at $5.32 on Thursday.
Analiz Makalesi • Mar 24

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analiz Makalesi • Nov 06

Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Alimera Sciences, Inc...
Analiz Makalesi • Aug 24

Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Even though Alimera Sciences, Inc. ( NASDAQ:ALIM ) posted strong earnings recently, the stock hasn't reacted in a large...
Analiz Makalesi • Feb 11

Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares

Alimera Sciences, Inc. ( NASDAQ:ALIM ) shareholders will doubtless be very grateful to see the share price up 97% in...

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ALIM şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: ALIM şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Alimera Sciences Piyasaya Karşı Temettü Getirisi
ALIM temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (ALIM)n/a
Pazarın Alt %25'i (US)1.4%
Pazarın En İyi %25'i (US)4.2%
Sektör Ortalaması (Pharmaceuticals)2.0%
Analist tahmini (ALIM) (3 yıla kadar)n/a

Önemli Temettü: ALIM şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ALIM şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: ALIM şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: ALIM herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Güçlü temettü ödeyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2024/09/18 16:13
Gün Sonu Hisse Fiyatı2024/09/13 00:00
Kazançlar2024/06/30
Yıllık Kazançlar2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Alimera Sciences, Inc. 12 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
James MolloyAlliance Global Partners
Andrew D'SilvaB. Riley Securities, Inc.
Caroline CornerCantor Fitzgerald & Co.